Purple Biotech (PPBT) Total Non-Current Liabilities (2016 - 2026)
Purple Biotech's (PPBT) quarterly Total Non-Current Liabilities came in at $170000.0 in Q2 2026, up 21.43% year-over-year from $140000.0 in Q2 2025, and up 6.25% quarter-over-quarter from $160000.0 in Q1 2026.
Powered by 
Analysis
Purple Biotech (PPBT) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Total Non-Current Liabilities for 11 consecutive years, with $170000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 21.43% year-over-year to $170000.0 in Q2 2026; TTM through Jun 2026 was $170000.0, a 21.43% increase from a year earlier, with the FY2025 full-year figure at $160000.0, up 14.29% from the prior year.
- Total Non-Current Liabilities was $170000.0 for Q2 2026 at Purple Biotech, up from $160000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $787000.0 in Q1 2022 and troughed at $140000.0 in Q4 2024.
- A 5-year average of $313277.8 and a median of $241000.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities sank 53.95% in 2024 and grew 21.43% in 2026, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at $466000.0 in 2022, then sank by 34.76% to $304000.0 in 2023, then slumped by 53.95% to $140000.0 in 2024, then climbed by 14.29% to $160000.0 in 2025, then rose by 6.25% to $170000.0 in 2026.
- The last three Total Non-Current Liabilities figures came in at $170000.0 (Q2 2026), $160000.0 (Q1 2026), and $160000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Purple Biotech | 291,843.46 | 291,843.46 | - | 170,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 170,000.00 |
| Mar 31, 2026 | 160,000.00 |
| Dec 31, 2025 | 160,000.00 |
| Sep 30, 2025 | 189,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Sep 30, 2024 | 179,000.00 |
| Jun 30, 2024 | 220,000.00 |
| Mar 31, 2024 | 262,000.00 |
| Dec 31, 2023 | 304,000.00 |
| Sep 30, 2023 | 333,000.00 |
| Jun 30, 2023 | 378,000.00 |
| Mar 31, 2023 | 419,000.00 |
| Dec 31, 2022 | 466,000.00 |
| Sep 30, 2022 | 501,000.00 |
| Jun 30, 2022 | 691,000.00 |
| Mar 31, 2022 | 787,000.00 |
| Dec 31, 2021 | 842,000.00 |
| Sep 30, 2021 | 828,000.00 |